# Prevail Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prevail-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.prevailtherapeutics.com
- Total disclosed funding: $107M
- Latest round: Series B (Mar 27, 2019)
- Investors on record: 12

## About

Prevail Therapeutics, Inc. focuses on developing groundbreaking gene therapies targeting neurodegenerative diseases and rare conditions, aiming to provide solutions for patients with limited treatment options.Prevail Therapeutics, Inc. is dedicated to developing gene therapies that address the causes of neurodegenerative diseases. Founded in 2017, the company is headquartered in New York, US. The CEO is Franz Hefti. In June 2019, Prevail raised USD 125 mn in an IPO. The company was acquired by Eli Lilly and Company in December 2020 for USD 880 mn, which could reach USD 1.04 bn upon regulatory approval of its products. The firm has engaged in 5 deals, with its most recent being on June 19, 2019.Prevail Therapeutics specializes in innovative gene therapies targeting neurodegenerative diseases and rare conditions, particularly Gaucher disease and Parkinson's disease associated with GBA1 genetic variants. Their therapies enhance or introduce specific enzymes to mitigate health issues related to these conditions, aiming to resolve fat accumulation in lysosomes which can lead to organ damage. The company primarily serves healthcare providers and institutions in North America and Europe that treat affected patients.The revenue model of Prevail Therapeutics is based on partnerships with healthcare institutions and collaborations with clinical trial participants for their gene therapies. Revenue is generated through clinical trial funding from providers seeking access to their therapies. The firm is also exploring commercialization opportunities by negotiating agreements with pharmaceutical companies as their products transition from clinical trials to market.Prevail Therapeutics plans to advance its pipeline of gene therapies targeting neurodegenerative diseases, with recent funding utilized to support ongoing clinical trials and development of new products. The company is focused on expanding its reach in North America and Europe. The acquisition by Eli Lilly will provide further resources for developing its therapies, which are expected to evolve into marketable products, creating significant revenue opportunities.

## Funding rounds

- Series B, Mar 27, 2019, $50M — OrbiMed Advisors, Alexandria Venture Investments, Adage Capital Management, Pontifax Venture Capital, Surveyor Capital, Omega Funds, AbbVie Ventures, BVF Partners, RA Capital Management, EcoR1 Capital, Boxer Capital
- Series A, Mar 7, 2018, $57M — OrbiMed Advisors, Alexandria Venture Investments, Adage Capital Management, Pontifax Venture Capital, Omega Funds, BVF Partners, RA Capital Management, EcoR1 Capital, Boxer Capital
- Seed, Jun 1, 2017 — OrbiMed Advisors, The Silverstein Foundation for Parkinson's with GBA

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A, Series B
- The Silverstein Foundation for Parkinson's with GBA — Seed
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Adage Capital Management — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A, Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- Surveyor Capital — Series B
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B